Catalonia strengthens its presence at the BIO International Convention 2025 with a large delegation and a busy agenda of international activities
The BIO International Convention 2025, held from June 16 to 19 in Boston and bringing together more than 20,000 international leaders from the biotechnology industry, featured a strong Catalan presence, both in terms of the number of participating companies and the international visibility and networking activities led by Biocat and Catalan institutions.
The Catalan delegation at the BIO International Convention 2025 saw significant growth compared to the previous year, increasing from 37 companies and organizations in 2024 to 51 in 2025—representing 61% of the total Spanish pavilion. This growth consolidates Catalonia as the most represented region in Spain and highlights the dynamism and growing international appeal of the Catalan biotechnology sector.
Among the Catalan companies and institutions present were: Ability Pharmaceuticals, Ahead Therapeutics, Almirall, Aromics, Aortyx, Bioingenium, Cebiotex, Clyype, CRG, Cytes Biotech, D-Sight, Deeplabs, Esteve, Ferrer, Gate2Brain, GatBio, Grifols, Hipra, Integra, Inveready, IRB Barcelona, Kymos, Minoryx, Nostrum Biodiscovery, Oniria Therapeutics, Peptomyc, Pulmobiotics, Reig Jofré, Remab Therapeutics, UAB, and Werfen, among others.
Biocat was present in Boston with its CEO, Robert Fabregat, and the Director of Innovation and Business Development, Núria Martí, leading the institutional agenda and launching initiatives to promote the Catalan ecosystem. The organization presented the portfolio of business opportunities in Catalonia’s health and life sciences sector to investors, pharmaceutical corporations, and other global strategic stakeholders, and facilitated connections with startups and scaleups through the Catalonia Health Investment Portal.
Biocat, together with the Barcelona City Council, held over 30 strategic meetings with international investors and major pharmaceutical companies such as Bayer, Novo Nordisk, Chiesi, and Menarini, highlighting the innovative potential and investment appeal of the BioRegion. Additionally, contacts were established with international delegations including Argentina, the Prague biotechnology cluster, the Massachusetts Life Sciences Center, and the Osaka Prefectural Government, among others, as well as with large Chinese, Korean, and Japanese multinationals—further expanding the global collaboration network.
One of the key moments of the week was the Catalonia Networking Reception, organized by Biocat, the Government of Catalonia, and the Barcelona City Council, with the support of HIPRA Biotech Services and the Catalan Biotech Group of Boston. The event, held on June 16 at Harpoon Brewery, brought together over 200 international professionals and featured the participation of the new Delegate of the Government of Catalonia to the U.S. and Canada, David Andrés Viñas.
Active Participation at RESI Boston
Throughout the week, Biocat also played an active role at the RESI Boston conference, which focuses on connecting early-stage startups with investors. The team held several meetings with investors and strategic partners and attended key sessions featuring investor panels.
The Catalan presence in Boston once again demonstrated the strength, innovative capacity, and global reach of the life sciences and health sector in Catalonia. The strong representation of companies and institutions, combined with the strategic engagement of Biocat and its partner institutions, further consolidates the BioRegion as a key international player and an attractive destination for investment and the development of new projects.